These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 37166370)

  • 1. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.
    Srivastava R; Dodda M; Zou H; Li X; Hu B
    Antioxid Redox Signal; 2023 Nov; 39(13-15):904-922. PubMed ID: 37166370
    [No Abstract]   [Full Text] [Related]  

  • 2. Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche.
    Liu M; Ji Z; Jain V; Smith VL; Hocke E; Patel AP; McLendon RE; Ashley DM; Gregory SG; López GY
    Acta Neuropathol Commun; 2024 Apr; 12(1):64. PubMed ID: 38650010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
    Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
    Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.
    Persano L; Rampazzo E; Basso G; Viola G
    Biochem Pharmacol; 2013 Mar; 85(5):612-622. PubMed ID: 23063412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma.
    Aderetti DA; Hira VVV; Molenaar RJ; van Noorden CJF
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):346-354. PubMed ID: 29684521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. For the next trick: new discoveries in radiobiology applied to glioblastoma.
    Debus J; Abdollahi A
    Am Soc Clin Oncol Educ Book; 2014; ():e95-9. PubMed ID: 24857153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
    Ngo MT; Harley BAC
    Biomaterials; 2019 Apr; 198():122-134. PubMed ID: 29941152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy.
    Tang X; Zuo C; Fang P; Liu G; Qiu Y; Huang Y; Tang R
    Front Oncol; 2021; 11():701291. PubMed ID: 34307170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors.
    Lauko A; Lo A; Ahluwalia MS; Lathia JD
    Semin Cancer Biol; 2022 Jul; 82():162-175. PubMed ID: 33640445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
    Pang L; Khan F; Dunterman M; Chen P
    Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
    Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines Targeting Glioma Stem Cells.
    Sabu A; Liu TI; Ng SS; Doong RA; Huang YF; Chiu HC
    ACS Appl Mater Interfaces; 2023 Jan; 15(1):158-181. PubMed ID: 35544684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
    Verdugo E; Puerto I; Medina MÁ
    Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.